BTIG Research Forecasts Strong Price Appreciation for Haemonetics (NYSE:HAE) Stock

Haemonetics (NYSE:HAE) had its price target lifted by research analysts at BTIG Research from $85.00 to $88.00 in a research report issued on Thursday, MarketBeat Ratings reports. The brokerage presently has a “buy” rating on the medical instruments supplier’s stock. BTIG Research’s price objective suggests a potential upside of 28.09% from the company’s current price.

A number of other analysts also recently weighed in on HAE. JPMorgan Chase & Co. reaffirmed a “neutral” rating and set a $62.00 price target (down previously from $85.00) on shares of Haemonetics in a report on Friday, August 8th. Barrington Research restated an “outperform” rating and set a $86.00 price objective on shares of Haemonetics in a research report on Tuesday, October 21st. Weiss Ratings cut Haemonetics from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Saturday, October 25th. Needham & Company LLC reissued a “buy” rating and set a $68.00 target price (down previously from $84.00) on shares of Haemonetics in a research note on Thursday, August 7th. Finally, Raymond James Financial downgraded shares of Haemonetics from a “strong-buy” rating to an “outperform” rating and lowered their price target for the stock from $105.00 to $78.00 in a report on Monday, August 11th. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has given a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $78.50.

Haemonetics Stock Up 2.4%

Shares of Haemonetics stock opened at $68.70 on Thursday. The firm has a market cap of $3.31 billion, a price-to-earnings ratio of 21.01, a P/E/G ratio of 0.91 and a beta of 0.43. The stock has a 50-day simple moving average of $51.53 and a 200-day simple moving average of $62.10. Haemonetics has a 52-week low of $47.31 and a 52-week high of $94.99. The company has a debt-to-equity ratio of 1.04, a current ratio of 1.72 and a quick ratio of 1.04.

Haemonetics (NYSE:HAE) last posted its quarterly earnings data on Thursday, November 6th. The medical instruments supplier reported $1.27 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.12 by $0.15. Haemonetics had a net margin of 12.14% and a return on equity of 26.64%. The business had revenue of $327.32 million during the quarter, compared to the consensus estimate of $311.61 million. During the same period in the prior year, the firm earned $1.12 EPS. Haemonetics’s quarterly revenue was down 5.3% compared to the same quarter last year. Haemonetics has set its FY 2026 guidance at 4.800-5.00 EPS. On average, equities research analysts expect that Haemonetics will post 4.55 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the stock. CenterBook Partners LP bought a new stake in shares of Haemonetics in the 3rd quarter valued at approximately $324,000. May Hill Capital LLC increased its holdings in shares of Haemonetics by 24.7% in the third quarter. May Hill Capital LLC now owns 22,348 shares of the medical instruments supplier’s stock valued at $1,089,000 after purchasing an additional 4,431 shares during the period. GSA Capital Partners LLP acquired a new position in Haemonetics during the third quarter valued at $618,000. State of New Jersey Common Pension Fund D lifted its holdings in Haemonetics by 38.4% in the third quarter. State of New Jersey Common Pension Fund D now owns 39,405 shares of the medical instruments supplier’s stock valued at $1,921,000 after acquiring an additional 10,937 shares during the period. Finally, ABN Amro Investment Solutions acquired a new position in Haemonetics in the 3rd quarter worth about $186,000. 99.67% of the stock is owned by hedge funds and other institutional investors.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.